Loading...
Please wait, while we are loading the content...
Similar Documents
The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Erin, E. McClelland Leaker, Brian Nicholson, Grant C. Tan, Andrew J. Green, Linda M. Neighbour, Helen Zacharasiewicz, Angela Turner, Jackie J. Barnathan, Elliot S. Barnes, Peter J. Hansel, Trevor T. |
| Copyright Year | 2006 |
| Abstract | RATIONALE Neutralization of tumor necrosis factor-alpha (TNF-alpha) is an effective antiinflammatory therapy for several chronic inflammatory diseases. METHODS AND OBJECTIVES We undertook a double-blind, placebo-controlled, parallel-group design study in 38 patients with moderate asthma treated with inhaled corticosteroids but symptomatic during a run-in phase. Infliximab (5 mg/kg) or placebo was administered by intravenous infusion at Weeks 0, 2, and 6. We assessed clinical response by monitoring lung function, symptoms, and inhaled beta(2)-agonist usage using hand-held electronic devices. RESULTS The primary endpoint, change in morning PEF at Days 50-56 compared with the last 7 d of the run-in, was not significantly different on treatment. However, infliximab was associated with a decrease in mean diurnal variation of PEF at Week 8 (p = 0.02; 95% confidence interval [CI], -8.1 to -0.72). Furthermore, there was a decrease in the number of patients with exacerbations of asthma (p = 0.01; 95% CI, 4.4 to 52.7) and an increased probability of freedom from exacerbation with time (p = 0.03) in patients on infliximab (n = 14) compared with placebo (n = 18). In addition, infliximab decreased levels of TNF-alpha (p = 0.01) and other cytokines in sputum supernatants. There were no serious adverse events related to the study agent. CONCLUSIONS Treatment with infliximab was well tolerated and caused a decrease in the number of patients with exacerbations in symptomatic moderate asthma. The promising preliminary findings underscore the need to evaluate therapy directed against TNF-alpha in larger trials enrolling patients with more severe asthma. |
| File Format | PDF HTM / HTML |
| PubMed reference number | 16840747 |
| Journal | Medline |
| Volume Number | 174 |
| Issue Number | 7 |
| Alternate Webpage(s) | https://minds.jcqhc.or.jp/past_archive/6_Minds_abstract/%E5%96%98%E6%81%AF%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E8%85%AB%E7%98%8D%E5%A3%8A%E6%AD%BB%E5%9B%A0%E5%AD%90%EF%BC%8D%CE%B1%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E3%83%A2%E3%83%8E%E3%82%AF%E3%83%AD%E3%83%BC%E3%83%8A%E3%83%AB%E6%8A%97%E4%BD%93%E3%81%AE%E4%BD%9C%E7%94%A8%E3%80%80%E3%80%90%EF%BC%B2%EF%BC%A9%EF%BC%B3%E3%80%91.pdf |
| Journal | American journal of respiratory and critical care medicine |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
